CompaniesAlladapt Immunotherapeutics

Alladapt Immunotherapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (2)
View all

Total Trials

2

As Lead Sponsor

2

As Collaborator

0

Total Enrollment

118

By Phase

PHASE1/PHASE2: 2

By Status

TERMINATED: 1COMPLETED: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
Today
NCT04856865
NCT05243719
Hover over trial bars to see details

Recent Trials

NCT05243719Lead Sponsor
Open-label Extension Study of ADP101
PHASE1/PHASE2Terminated
45 participants
Started: Mar 14, 2022 · Completed: Feb 27, 2024
NCT04856865Lead Sponsor
ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
PHASE1/PHASE2Completed
73 participants
Started: Apr 20, 2021 · Completed: Dec 13, 2022